Marinus Pharmaceuticals Inc. (MRNS) NASDAQ

$5.80 0 (0.00%)

Market Cap: $215.76M

As of 08/15/22 11:16 AM EDT. Market open.

(MRNS)

Marinus Pharmaceuticals Inc. (MRNS) NASDAQ

$5.80 0 (0.00%)

Market Cap: $215.76M

As of 08/15/22 11:16 AM EDT. Market open.

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms ... read more

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
69
CEO Compensation (Base)
$520,000
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$5.95
Previous Close
$5.80
Days Range
$5.75 - $5.93
52 week range
$3.97 - $13.15
Volume
40,839
Avg. Volume (30 days)
190,108
Market Cap
$215.76M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
37,199,150
Open
$5.95
Previous Close
$5.80
Days Range
$5.75 - $5.93
52 week range
$3.97 - $13.15
Volume
40,839
Avg. Volume (30 days)
190,108
Market Cap
$215.76M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
37,199,150

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR MARINUS PHARMACEUTICALS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
VITULLO NICOLE Director Mar 15, 2021 Sale $15.87 4,250 67,447 0 Mar 16, 2021, 04:58 PM
Smith Edward F Former VP, CFO & Treasurer Mar 09, 2021 Option Exercise $4.16 35,927 149,456 53,644 Mar 11, 2021, 04:04 PM
Smith Edward F Former VP, CFO & Treasurer Mar 09, 2021 Sale $17.80 40,356 718,337 13,288 Mar 11, 2021, 04:04 PM
Smith Edward F CFO Jan 30, 2020 Sale $2.05 2,380 4,879 17,717 Feb 03, 2020, 06:29 PM
Braunstein Scott Chief Executive Officer Dec 13, 2019 Buy $1.25 100,000 125,000 100,000 Dec 13, 2019, 04:08 PM
Smith Edward F CFO May 16, 2019 Sale $5.03 24,211 121,781 20,097 May 20, 2019, 04:20 PM
Cashman Christopher Michael CEO Mar 18, 2019 Option Exercise $1.04 31,662 32,928 271,423 Mar 20, 2019, 05:57 PM
Cashman Christopher Michael CEO Jan 28, 2019 Sale $3.13 8,142 25,484 239,761 Jan 30, 2019, 04:09 PM
Smith Edward F CFO Jan 29, 2019 Sale $3.06 2,492 7,626 44,308 Jan 30, 2019, 04:08 PM
Smith Edward F CFO Jan 29, 2018 Sale $7.91 3,000 23,730 49,800 Jan 29, 2018, 08:00 PM
Cashman Christopher Michael CEO Jan 18, 2018 Sale $6.28 9,566 60,074 247,903 Jan 22, 2018, 08:41 PM
Bain Capital Life Sciences Investors, LLC 10% Owner Dec 19, 2017 Sale $7.43 150,000 1,114,670 4,032,682 Dec 19, 2017, 08:30 PM
Bain Capital Life Sciences Investors, LLC 10% Owner Dec 18, 2017 Sale $7.50 300,000 2,251,440 4,127,453 Dec 19, 2017, 08:30 PM
Bain Capital Life Sciences Investors, LLC 10% Owner Dec 15, 2017 Sale $8.10 822,547 6,658,691 4,530,335 Dec 19, 2017, 08:30 PM
Mehra Anand 10% Owner Oct 20, 2016 Sale $1.39 750,683 1,042,699 1,134,851 Oct 24, 2016, 04:49 PM
Canaan VII LP 10% Owner Aug 05, 2016 Sale $1.50 129,204 193,806 1,870,733 Aug 09, 2016, 10:03 AM
Canaan VII LP 10% Owner Aug 08, 2016 Sale $1.50 19,950 29,925 1,850,783 Aug 09, 2016, 10:03 AM
Canaan VII LP 10% Owner Aug 04, 2016 Sale $1.50 3,329 4,994 1,999,937 Aug 05, 2016, 10:18 AM
Canaan VII LP 10% Owner Aug 03, 2016 Sale $1.50 142,254 213,381 2,003,266 Aug 05, 2016, 10:18 AM
Canaan VII LP 10% Owner Jul 29, 2016 Sale $1.71 24,540 41,963 2,145,520 Aug 02, 2016, 12:22 PM
Canaan VII LP 10% Owner Jul 26, 2016 Sale $1.81 20,380 36,888 2,170,269 Jul 27, 2016, 04:30 PM
Canaan VII LP 10% Owner Jul 27, 2016 Sale $1.80 209 376 2,170,060 Jul 27, 2016, 04:30 PM
Canaan VII LP 10% Owner Jul 25, 2016 Sale $1.86 137,617 255,968 2,190,649 Jul 26, 2016, 10:08 AM
Canaan VII LP 10% Owner Jul 22, 2016 Sale $1.94 133,133 258,278 2,328,266 Jul 26, 2016, 10:08 AM
Cashman Christopher Michael President and CEO Feb 09, 2016 Option Exercise $1.04 24,684 25,671 140,769 Feb 11, 2016, 05:17 PM
Cashman Christopher Michael President and CEO Nov 06, 2015 Buy $5.61 3,561 19,977 116,085 Feb 11, 2016, 05:17 PM
Bloch Stephen M Director Sep 28, 2015 Option Exercise $1.04 39,550 41,132 39,550 Feb 04, 2016, 06:48 PM
Bloch Stephen M Director Sep 28, 2015 Option Exercise $1.04 39,550 41,132 39,550 Sep 28, 2015, 08:12 PM
MAYLEBEN TIMOTHY M Director Jul 16, 2015 Option Exercise $1.04 42,550 44,252 42,550 Jul 17, 2015, 04:01 PM
Cashman Christopher Michael President and CEO Jul 01, 2015 Option Exercise $1.04 14,086 14,649 112,524 Jul 02, 2015, 04:08 PM
Bloch Stephen M Director Jun 10, 2015 Option Exercise $1.04 3,000 3,120 3,000 Jun 11, 2015, 05:26 PM
Farfel Gail M Chief Clinical Dev & Reg Offic Apr 21, 2015 Option Exercise $1.04 30,000 31,200 30,000 Apr 23, 2015, 04:48 PM
Farfel Gail M Chief Clinical Dev & Reg Offic Apr 21, 2015 Sale $9.48 30,000 284,511 0 Apr 23, 2015, 04:48 PM
Cashman Christopher Michael PRESIDENT AND CEO Mar 06, 2015 Option Exercise $1.04 17,608 18,312 98,438 Mar 10, 2015, 01:16 PM
Cashman Christopher Michael PRESIDENT AND CEO Oct 08, 2014 Option Exercise $1.04 80,830 84,063 80,830 Oct 09, 2014, 04:05 PM
Domain Partners VI, L.P. 10% Owner Aug 05, 2014 Buy $8.00 419,744 3,357,952 2,476,886 Aug 07, 2014, 03:06 PM
Mehra Anand Director Aug 05, 2014 Buy $8.00 750,683 6,005,464 1,859,639 Aug 07, 2014, 12:43 PM
Canaan VII L P Director Aug 05, 2014 Buy $8.00 625,000 5,000,000 2,461,398 Aug 06, 2014, 09:03 AM
Bloch Stephen M Director Aug 05, 2014 Buy $8.00 625,000 5,000,000 2,461,398 Aug 06, 2014, 09:03 AM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
VITULLO NICOLE Director 03/15/2021 67,447
Smith Edward F Former VP, CFO & Treasurer 03/09/2021 149,456
Smith Edward F Former VP, CFO & Treasurer 03/09/2021 718,337
Smith Edward F CFO 01/30/2020 4,879
Braunstein Scott Chief Executive Officer 12/13/2019 125,000
Smith Edward F CFO 05/16/2019 121,781
Cashman Christopher Michael CEO 03/18/2019 32,928
Cashman Christopher Michael CEO 01/28/2019 25,484
Smith Edward F CFO 01/29/2019 7,626
Smith Edward F CFO 01/29/2018 23,730
Cashman Christopher Michael CEO 01/18/2018 60,074
Bain Capital Life Sciences Investors, LLC 10% Owner 12/19/2017 1,114,670
Bain Capital Life Sciences Investors, LLC 10% Owner 12/18/2017 2,251,440
Bain Capital Life Sciences Investors, LLC 10% Owner 12/15/2017 6,658,691
Mehra Anand 10% Owner 10/20/2016 1,042,699
Canaan VII LP 10% Owner 08/05/2016 193,806
Canaan VII LP 10% Owner 08/08/2016 29,925
Canaan VII LP 10% Owner 08/04/2016 4,994
Canaan VII LP 10% Owner 08/03/2016 213,381
Canaan VII LP 10% Owner 07/29/2016 41,963
Canaan VII LP 10% Owner 07/26/2016 36,888
Canaan VII LP 10% Owner 07/27/2016 376
Canaan VII LP 10% Owner 07/25/2016 255,968
Canaan VII LP 10% Owner 07/22/2016 258,278
Cashman Christopher Michael President and CEO 02/09/2016 25,671
Cashman Christopher Michael President and CEO 11/06/2015 19,977
Bloch Stephen M Director 09/28/2015 41,132
Bloch Stephen M Director 09/28/2015 41,132
MAYLEBEN TIMOTHY M Director 07/16/2015 44,252
Cashman Christopher Michael President and CEO 07/01/2015 14,649
Bloch Stephen M Director 06/10/2015 3,120
Farfel Gail M Chief Clinical Dev & Reg Offic 04/21/2015 31,200
Farfel Gail M Chief Clinical Dev & Reg Offic 04/21/2015 284,511
Cashman Christopher Michael PRESIDENT AND CEO 03/06/2015 18,312
Cashman Christopher Michael PRESIDENT AND CEO 10/08/2014 84,063
Domain Partners VI, L.P. 10% Owner 08/05/2014 3,357,952
Mehra Anand Director 08/05/2014 6,005,464
Canaan VII L P Director 08/05/2014 5,000,000
Bloch Stephen M Director 08/05/2014 5,000,000
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2021
09/30/2021
-0.01%
1Q
12/31/2021
03/31/2021
0.17%
3Q
12/31/2021
12/31/2020
34.45%
4Q
12/31/2021
09/30/2020
42.45%
5Q
12/31/2021
12/31/2019
-32.74%
8Q
12/31/2021
09/30/2019
-30.18%
9Q
12/31/2021
06/30/2019
-30.16%
10Q
12/31/2021
03/31/2019
-30.12%
11Q
12/31/2021
12/31/2018
-10.35%
12Q
12/31/2021
09/30/2018
-9.23%
13Q
12/31/2021
06/30/2018
-9.21%
14Q
12/31/2021
03/31/2018
-9.19%
15Q
Load More

Period of Report: 12/31/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2021
-0.01%
1Q
03/31/2021
0.17%
3Q
12/31/2020
34.45%
4Q
09/30/2020
42.45%
5Q
12/31/2019
-32.74%
8Q
09/30/2019
-30.18%
9Q
06/30/2019
-30.16%
10Q
03/31/2019
-30.12%
11Q
12/31/2018
-10.35%
12Q
09/30/2018
-9.23%
13Q
06/30/2018
-9.21%
14Q
03/31/2018
-9.19%
15Q
Load More